The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study
Open accessAbstract
Aims/hypothesis Glucagon-like peptide 1 (GLP-1) reduces appetite and energy intake in humans, whereas the other incretin hormone, glucose-dependent insulinotropic polypeptide (GIP), seems to have no effect on eating behaviour. Interestingly, studies in rodents have shown that concomitant activation of GIP and GLP-1 receptors may potentiate the satiety-promoting effect of GLP-1, and a novel dual GLP-1/GIP receptor agonist was recently shown to trigger greater weight losses compared with a GLP-1 receptor agonist in individuals with type 2 diabetes. The aim of this study was to delineate the effects of combined GIP and GLP-1 receptor activation on energy intake, appetite and resting energy expenditure in humans.Methods We examined 17 overweight/obese men in a crossover design with 5 study days. On day 1, a 50 g OGTT was performed; on the following 4 study days, the men received an isoglycaemic i.v. glucose infusion (IIGI) plus saline (154 mmol/l NaCl; placebo), GIP (4 pmol kg-1 min-1), GLP-1 (1 pmol kg-1 min-1) or GIP+GLP-1 (4 and 1 pmol kg-1 min-1, respectively). All IIGIs were performed in a randomised order blinded for the participant and the investigators. The primary endpoint was energy intake as measured by an ad libitum meal after 240 min. Secondary endpoints included appetite ratings and resting energy expenditure, as well as insulin, C-peptide and glucagon responses.Results Energy intake was significantly reduced during IIGI+GLP-1 compared with IIGI+saline infusion (2715 ± 409 vs 4483 ± 568 kJ [mean ± SEM, n = 17], p = 0.014), whereas there were no significant differences in energy intake during IIGI+GIP (4062 ± 520 kJ) or IIGI+GIP+GLP-1 (3875 ± 451 kJ) infusion compared with IIGI+saline (p = 0.590 and p = 0.364, respectively). Energy intake was higher during IIGI+GIP+GLP-1 compared with IIGI+GLP-1 infusion (p = 0.039).Conclusions/interpretation While GLP-1 infusion lowered energy intake in overweight/obese men, simultaneous GIP infusion did not potentiate this GLP-1-mediated effect.Trial registration ClinicalTrials.gov NCT02598791 FUNDING: This study was supported by grants from the Innovation Fund Denmark and the Vissing Foundation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“despite that this additive effect in food intake and glycaemia was not observed in some acute clinical studies [41, 42].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [42]
Experimental — accuracy not yet measuredIn the citing paper
“Seventeen overweight or obese males were given either GIP or GLP-1 alone for 5 days, or GIP+GLP-1 at the same time, and allowed to eat ad libitum food 240 min later, and there was no effect on energy intake in the GIP group.”
From Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand? (2021) · cites this paper as [68]
In the citing paper
“Energy intake decreased in the GLP-1 administration group, but energy intake increased more in the GIP+GLP-1 combination administration group (P = 0.039) [68].”
From Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand? (2021) · cites this paper as [68]
In the citing paper
“Energy intake decreased in the GLP-1 administration group, but energy intake increased more in the GIP+GLP-1 combination administration group (P = 0.039) [68].”
From Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand? (2021) · cites this paper as [68]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pharmacology, physiology, and mechanisms of incretin hormone action.
Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402
Self-citationInhibition of gastric inhibitory polypeptide signaling prevents obesity
Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H., Fujimoto, S., Oku, A., Tsuda, K., Toyokuni, S., et al. (2002) · Nature Medicine · doi:10.1038/nm727 · Cited by 963
Self-citationTissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans
Ørskov, C., Rabenhøj, L., Wettergren, A., Kofod, H., & Holst, J. J. (1994) · Diabetes · doi:10.2337/diab.43.4.535 · Cited by 916
Self-citationScience Translational Medicine
(2013) · Science Translational Medicine · doi:10.1126/scitranslmed · Cited by 880
Frias, J. P., Nauck, M. A., Van, J., Kutner, M. E., Cui, X., Benson, C., Urva, S., Gimeno, R. E., Milicevic, Z., Robins, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32260-8 · Cited by 815
Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans
Finan, B., Ma, T., Ottaway, N., Müller, T. D., Habegger, K. M., Heppner, K. M., Kirchner, H., Holland, J., Hembree, J., Raver, C., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007218 · Cited by 696
Blundell, J., Finlayson, G., Axelsen, M., Flint, A., Gibbons, C., Kvist, T., & Hjerpsted, J. B. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12932 · Cited by 693
Verdich, C., Flint, A., Gutzwiller, J., Näslund, E. B., Beglinger, C., Hellström, P. M., Long, S. J., Morgan, L., Holst, J. J., & Astrup, A. V. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.9.7877 · Cited by 657
Self-citationNauck, M. A., Bartels, E., Ørskov, C., Ebert, R., & Creutzfeldt, W. (1993) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.76.4.8473405 · Cited by 505
Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men.
Näslund, E., Barkeling, B., King, N., Gutniak, M., Blundell, J., Holst, J., Rössner, S., & Hellström, P. (1999) · International Journal of Obesity · doi:10.1038/sj.ijo.0800818 · Cited by 468
Self-citationVilsbøll, T., Agersø, H., Krarup, T., & Holst, J. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021053 · Cited by 444
Self-citationFlint, A., Raben, A., Ersbøll, A., Holst, J., & Astrup, A. (2001) · International Journal of Obesity · doi:10.1038/sj.ijo.0801627 · Cited by 384
Self-citationFrias, J. P., Bastyr, E. J., Vignati, L., Tschöp, M. H., Schmitt, C., Owen, K., Christensen, R. H., & DiMarchi, R. D. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.07.011 · Cited by 321
Elahi, D., McAloon-Dyke, M., Fukagawa, N. K., Meneilly, G. S., Sclater, A. L., Minaker, K. L., Habener, J. F., & Andersen, D. K. (1994) · Regulatory Peptides · doi:10.1016/0167-0115(94)90136-8 · Cited by 308
McClean, P. L., Irwin, N., Cassidy, R. S., Holst, J. J., Gault, V. A., & Flatt, P. R. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00460.2007 · Cited by 239
Self-citationVilsbøll, T., Knop, F. K., Krarup, T., Johansen, A., Madsbad, S., Larsen, S., Hansen, T. W., Pedersen, O. B., & Holst, J. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030738 · Cited by 230
Self-citationMentis, N., Vardarli, I., Köthe, L. D., Holst, J. J., Deacon, C. F., Theodorakis, M., Meier, J. J., & Nauck, M. A. (2011) · Diabetes · doi:10.2337/db10-1332 · Cited by 197
Self-citationKnop, F. K., Aaboe, K., Vilsbøll, T., Vølund, A., Holst, J. J., Krarup, T., & Madsbad, S. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01549.x · Cited by 196
Self-citationIncretin Hormone and Insulin Responses to OralVersusIntravenous Lipid Administration in Humans
Lindgren, O., Carr, R. D., Deacon, C. F., Holst, J. J., Pacini, G., Mari, A., & Åhrén, B. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0266 · Cited by 192
Self-citationKim, S.-J., Nian, C., Karunakaran, S., Clee, S. M., Isales, C. M., & McIntosh, C. H. S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040156 · Cited by 182
Althage, M. C., Ford, E. L., Wang, S., Tso, P., Polonsky, K. S., & Wice, B. M. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m710466200 · Cited by 180
Reappraisal of GIP Pharmacology for Metabolic Diseases
Finan, B., Müller, T. D., Clemmensen, C., Perez-Tilve, D., DiMarchi, R. D., & Tschöp, M. H. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.03.005 · Cited by 180
Horowitz, M., Flint, A., Jones, K. L., Hindsberger, C., Rasmussen, M. F., Kapitza, C., Doran, S., Jax, T., Zdravkovic, M., & Chapman, I. M. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.02.016 · Cited by 179
ISEC: a program to calculate insulin secretion.
Hovorka, R., Soons, P., & Young, M. A. (1996) · Computer Methods and Programs in Biomedicine · doi:10.1016/0169-2607(96)01755-5 · Cited by 169
Reproducibility and power of ad libitum energy intake assessed by repeated single meals
Gregersen, N. T., Flint, A., Bitz, C., Blundell, J. E., Raben, A., & Astrup, A. V. (2008) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/87.5.1277 · Cited by 140
Let's stay together: Towards traffic aware virtual machine placement in data centers
Li, X., Wu, J., Tang, S., & Lu, S. (2014) · IEEE Conference on Computer Communications (INFOCOM) · doi:10.1109/infocom.2014.6848123 · Cited by 129
Gault, V. A., Kerr, B. D., Harriott, P., & Flatt, P. R. (2011) · Clinical Science · doi:10.1042/cs20110006 · Cited by 125
Nørregaard, P. K., Deryabina, M. A., Tofteng Shelton, P., Fog, J. U., Daugaard, J. R., Eriksson, P., Larsen, L. F., & Jessen, L. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13034 · Cited by 116
Self-citationSparre‐Ulrich, A. H., Hansen, L. S., Svendsen, B., Christensen, M., Knop, F. K., Hartmann, B., Holst, J. J., & ROSENKILDE, M. M. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13323 · Cited by 112
Self-citationThe Glucostatic Theory of Appetite Control and the Risk of Obesity and Diabetes
Chaput, J.-P., & Tremblay, A. (2009) · International Journal of Obesity · doi:10.1038/ijo.2008.221 · Cited by 111
On the role of glucose-dependent insulintropic polypeptide in postprandial metabolism in humans
Asmar, M., Tangaa, W., Madsbad, S., Hare, K. J., Astrup, A. V., Flint, A., Bülow, J., & Holst, J. J. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00639.2009 · Cited by 83
Self-citationVilsbøll, T., Agersø, H., Lauritsen, T. L. B., Deacon, C. F., Aaboe, K., Madsbad, S., Krarup, T., & Holst, J. J. (2006) · Regulatory Peptides · doi:10.1016/j.regpep.2006.07.007 · Cited by 75
Self-citationSchmitt, C., Portron, A., Jadidi, S., Sarkar, N., & DiMarchi, R. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13024 · Cited by 74
Daousi, C., Wilding, J. P. H., Aditya, S., Durham, B. H., Cleator, J., Pinkney, J. H., & Ranganath, L. R. (2009) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03451.x · Cited by 64
Effects of glucagon‐like peptide 1 (7–36 amide) on whole‐body protein metabolism in healthy man
Shalev, A., Holst, J. J., & Keller, U. B. (1997) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.1997.540613.x · Cited by 62
Self-citationCalanna, S., Piro, S., Pino, A. D., Zagami, R. M., Urbano, F., Purrello, F., & Rabuazzo, A. M. (2013) · Obesity · doi:10.1002/oby.20017 · Cited by 37
Rudovich, N. N., Pivovarova‐Ramich, O., Gögebakan, Ö., Sparwaßer, A., Doehner, W., Anker, S. D., Arafat, A. M., Bergmann, A., Nauck, M. A., & Pfeiffer, A. F. H. (2014) · Diabetes Care · doi:10.2337/dc14-1452 · Cited by 12
“Let's Stay Together”; GIP and GLP-1 dual agonism in the treatment of metabolic disease
DiMarchi, R. D. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.10.004 · Cited by 9
Cited by
Sorted by citations
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Self-citationCardiovascular disease in type 2 diabetes mellitus: progress toward personalized management
Ma, C.-X., Ma, X.-N., Guan, C.-H., Li, Y.-D., Mauricio, D., & Fu, S.-B. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01516-6 · Cited by 464
Pharmacotherapy of obesity: an update on the available medications and drugs under investigation
Chakhtoura, M., Haber, R., Ghezzawi, M., Rhayem, C., Tcheroyan, R., & Mantzoros, C. S. (2023) · eClinicalMedicine · doi:10.1016/j.eclinm.2023.101882 · Cited by 462
Nauck, M. A., & D‘Alessio, D. A. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01604-7 · Cited by 407
Nauck, M. A., Quast, D. R., Wefers, J., & Pfeiffer, A. F. H. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14496 · Cited by 388
Metadata
- Authors
- Bergmann, N. C., Lund, A., Gasbjerg, L. S., Meessen, E. C. E., Andersen, M. M., Bergmann, S., Hartmann, B., Holst, J. J., Jessen, L., Christensen, M. B., Vilsbøll, T., & Knop, F. K.
- Affiliations
- University of Copenhagen (DK)
- Amsterdam UMC Location University of Amsterdam (NL)
- Gentofte Hospital (DK)
- Zealand Pharma (Denmark) (DK)
- Corresponding author
- Knop, Filip K.
- ORCID
- Venue
- Diabetologia
- Published
- 2019-01-25
- Volume
- 62
- Issue
- 4
- Pages
- 665-675
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W2911644854
- Cited by
- 142
- References
- 38
- Citations by year
- 2026: 9 · 2025: 28 · 2024: 19 · 2023: 17 · 2022: 19 · 2021: 22 · 2020: 13 · 2019: 14
- FWCI
- 9.39
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Diabetologia (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- The Vissing Foundation
- The Innovation Fund Denmark
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, GIP/GLP-1 receptor agonist, energy intake, appetite, resting energy expenditure, incretins, satiety, obesity, overweight
- MeSH terms
- Adult, Aged, Appetite, Blood Glucose, Energy Intake, Calorimetry, Double-Blind Method, Energy Metabolism, Gastric Inhibitory Polypeptide, Glucagon, Humans, Insulin, Male, Middle Aged, Obesity, Weight Loss, Cross-Over Studies, Overweight, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
